Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia

被引：1

作者：

Rindone, JP ^{[1
]}

Dzurick, J ^{[1
]}

Hiller, D ^{[1
]}

Peralta, B ^{[1
]}

机构：

[1] VA Med Ctr 316, Prescott, AZ 86313 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2001年 / 87卷 / 03期

关键词：

D O I：

10.1016/S0002-9149(00)01372-2

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Atorvastatin 15 mg/week was administered to 21 patients with hypercholesterolemia for 2 months. The mean low-density lipoprotein concentration decreased by 20% after treatment.

引用

页码：341 / +

页数：3

共 5 条

[1]

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects [J].

Cilla, DD ;

Whitfield, LR ;

Gibson, DM ;

Sedman, AJ ;

Posvar, EL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :687-695

[2]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[3]

GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015

[4]

Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES study) [J].

Jones, P ;

Kafonek, S ;

Laurora, I ;

Hunninghake, D .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (05) :582-587

[5]

REDUCTION OF LDL CHOLESTEROL BY 25-PERCENT TO 60-PERCENT IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA BY ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR [J].

NAWROCKI, JW ;

WEISS, SR ;

DAVIDSON, MH ;

SPRECHER, DL ;

SCHWARTZ, SL ;

LUPIEN, PJ ;

JONES, PH ;

HABER, HE ;

BLACK, DM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (05) :678-682

← 1 →